Tafamidis Meglumine
CAS 951395-20-7 13 FDA-DMF suppliersSmall Molecule
Overview
Tafamidis Meglumine is a chaperone amyloid fibril inhibitor used for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin-related hereditary amyloid polyneuropathy (hATTR-PN). It stabilizes transthyretin, thus preventing the misfolding and deposition of amyloid fibrils in tissues.
Therapeutic areas
NeurologyCardiology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.